Search Bar & Filters
Found 28 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying pediatric cryptosporidiosis to better understand how this infection presents and progresses in children aged 6 to 59 months. The focus is on characterizing the clinical features and course of diarrhea caused by Cryptosporidium, a parasite common in certain regions. This observational study aims to gather detailed information on symptoms and outcomes in affected children. Participants are children with diarrhea due to Cryptosporidium infection confirmed by specific stool tests. The study observes children with varying durations of diarrheafrom acute to chronicand different nutritional statuses. The study follows children for up to 21 days, monitoring diarrhea severity, dehydration, and parasite presence without administering any treatment. During participation, children will be assessed at multiple time points including baseline, days 3, 7, 14, and up to day 21. Researchers will collect stool samples and evaluate dehydration severity, diarrhea resolution time, and parasite shedding. Additional factors like age, nutritional status, and breastfeeding history will be analyzed to understand their association with illness duration and severity. Participants will be followed closely to capture the natural course of infection and symptoms.
Actively Recruiting
Researchers are studying whether longer admission to the Kangaroo Mother Care KMC ward after neonatal intensive care unit NICU discharge can reduce postpartum depression PPD in mothers of low birthweight preterm infants in low-resource settings. The trial also examines whether extended KMC improves infants neurodevelopment at 6, 12, and 18 months, explores barriers to practicing KMC after hospital discharge, assesses paternal depression prevalence, and evaluates cost-effectiveness of extended KMC admission. The trial randomly assigns mother-infant pairs to either an intervention group admitted to the KMC ward for more than 2 days after NICU discharge or a control group admitted for less than 2 days. Both groups receive support for KMC, breastfeeding, and preterm infant care during their stay in the KMC ward prior to going home. The study includes in-depth interviews with parents and family members to understand KMC uptake and measures various maternal and infant health outcomes over time. Participants will be monitored with clinic visits at 2 weeks, 6-8 weeks, and follow-ups at 6, 12, and 18 months. During these visits, mothers are screened for postpartum depression and social support, fathers are screened for depression, and infants undergo neurodevelopmental assessments. Researchers will collect data on KMC practice hours, breastfeeding, infant growth, morbidity, mortality, vaccine adherence, and costs related to care. The total study duration extends up to 18 months for infant follow-up.
Actively Recruiting
Researchers are studying advanced HIV disease AHD among adults in Zambia who are starting or restarting antiretroviral therapy ART. The study aims to understand the characteristics, care, and outcomes of clients diagnosed with AHD during their first six months on ART, a period when risks of disengagement from care and death are highest. This observational study collects data to help the Zambia Ministry of Health and partners improve treatment guidelines and interventions for AHD patients. The study involves several groups a prospective cohort of adults newly screened for AHD, a hybrid cohort of adults screened in the previous year, an inpatient cohort of adults hospitalized for AHD management, and a provider cohort of health workers involved in AHD care. Participants will be enrolled based on ART initiation status and AHD screening, with data collected from medical records, surveys, interviews, and focus groups. Data collection includes retrospective and prospective periods, covering up to 12 months before and after enrollment. Participants will undergo clinical record reviews and complete surveys and interviews about their care experiences and socioeconomic status. Healthcare providers at study sites will also provide input through surveys and interviews. Researchers will measure outcomes such as retention in care and viral suppression at 6 and 12 months, inpatient characteristics, guideline adherence, and costs. The study will monitor participants during their first six months on ART, with some follow-up extending to 12 months, to better understand and support AHD clients in Zambia.
Actively Recruiting
Tuberculosis TB remains a major global health issue with over 3 million undiagnosed cases and 1 million deaths annually. This research aims to improve TB diagnosis by evaluating faster, simpler, and less expensive point-of-care tests that do not rely on sputum samples. The study focuses on adolescents and adults with symptoms or risk factors for TB presenting at outpatient clinics in high-burden countries. Participants will be tested using novel TB triage and diagnostic tools, including tongue swab-based molecular assays designed for near point-of-care use. The study will compare these new tests against established methods like sputum Xpert MTBRIF Ultra and mycobacterial culture. Additionally, the usability and acceptability of these tests will be assessed by observing and surveying health workers involved in routine TB testing. Participants will undergo screening for TB symptoms or risk factors and provide samples for diagnostic testing. Researchers will evaluate how often the new tests correctly identify TB cases and non-cases over two years. Health workers will be surveyed to understand the ease and practicality of using the new tests. The study is expected to continue until September 2028, with ongoing monitoring of test performance and user feedback.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of antibiotic treatment on asymptomatic bacteriuria AB during pregnancy in low- and middle-income countries. This phase 3 randomized controlled trial aims to reduce the incidence of small vulnerable newborns SVN and stillbirths SB, contributing to global health goals to prevent early childhood deaths. The study involves pregnant individuals and newborns across seven international sites collaborating with the NICHD Global Network for Womens and Childrens Health Research. Participants with AB are randomly assigned to one of two groups one group receives a 7-day course of oral nitrofurantoin monohydratemacrocrystals at 100 mg twice daily 14 doses total, while the other group receives a matching placebo on the same schedule. The study compares the impact of this antibiotic treatment versus placebo during pregnancy. During the study, participants will complete screening, randomization, treatment, and follow-up visits, with monitoring continuing until 42 days after birth. Researchers will assess the number of small vulnerable newborns or stillbirths as the main outcome. Participants must remain in the study area for the full postpartum follow-up period, during which health and safety are monitored carefully.
Actively Recruiting
Adolescents and young adults living with HIV in Zambia face a higher risk of premature death from cancers such as Kaposi sarcoma, non-Hodgkins lymphoma, and cervical cancer compared to their uninfected peers. This research evaluates the ARROW program, which uses peer support strategies at multiple levels to enhance early cancer diagnosis and improve adherence to cancer treatment in this group. The study aims to compare ARROW with a one-time education campaign to find the best approach to reduce cancer mortality in this vulnerable population. The ARROW program includes peer counselors supporting patients directly, peer-led education sessions for healthcare providers, and a collaborative forum involving health administrators and policymakers to address systemic barriers. Participants are randomized to either receive these comprehensive ARROW strategies or one-time educational materials alongside usual care. This interventional study uses implementation science to assess the programs effectiveness, feasibility, and cost-effectiveness over time. Participants aged 15 to 39 years who have been on antiretroviral therapy for at least six months will engage in this study over a three-year period. Researchers will measure the proportion of participants completing cancer screenings and recommended treatments within 12 months of enrollment or diagnosis. Additional assessments include timely diagnostic procedures, treatment initiation, and survival rates. The study also monitors implementation outcomes and economic impact to support future scaling and policy decisions.
Actively Recruiting
Researchers are evaluating the diagnostic accuracy and operational features of the Bioneer Accupower Q-RFIA PCR kit used on the IRON qPCR system for detecting tuberculosis TB and resistance to key anti-TB drugs including isoniazid, rifampicin, fluoroquinolones, and aminoglycosides. This multicenter observational study aims to support global and national decisions by providing robust evidence on the validity of this rapid test, which integrates sample preparation and can deliver results within 30 minutes. The study compares the investigational assay with existing diagnostic tests and uses culture and molecular sequencing as reference standards. Participants suspected of pulmonary TB will provide sputum samples that will be tested with the Bioneer RFIA kit and comparator assays such as Xpert MTBRIF Ultra and Xpert MTBXDR. The study assesses both direct sputum samples and cultured isolates to compare diagnostic performance and resolve any discordant results. Additional tests include smear microscopy, culture on different media, phenotypic drug susceptibility testing, and whole genome sequencing for samples with discrepant resistance results. Retrospective specimens from biobanks may also be included for testing. During the study, participants provide sputum specimens which undergo multiple diagnostic tests at various laboratories following standardized procedures. Data on test results and resistance detection are recorded systematically. The primary outcomes include diagnostic accuracy for TB detection and drug resistance identification over 8 months. The study follows rigorous quality control, safety, and ethical standards to ensure reliable results and participant safety throughout the study period ending in mid-2027.
Actively Recruiting
This research aims to determine if continuing caffeine citrate treatment after hospital discharge can prevent apneic events causing sick visits in moderately preterm infants. It also evaluates whether caffeine use improves developmental outcomes at 12 months of age. The study compares caffeine citrate to a placebo to assess its effects on apnea and infant development. Participants receive either caffeine citrate at 20mgkgday or a placebo of sterile water orally once daily for up to 28 days following hospital discharge. The doses are prepared based on the infants weight prior to discharge and are not adjusted afterward. Parents or guardians administer the medication daily and keep a diary of symptoms and apneic events. Weekly phone calls monitor the infants condition until day 28, with an additional follow-up call at 2 months. Participants return to the clinic for physical examinations at 28 days and 2 months after discharge. At 12 months, infants undergo a neurodevelopmental assessment using the Ages and Stages Questionnaire. Data collected includes the number of apneic events, healthcare visits related to apnea, all-cause sick visits, neonatal mortality, and developmental outcomes. Study data is securely stored and managed to protect participant confidentiality throughout the trial.
Actively Recruiting
This trial evaluates oral caffeine treatment compared to placebo in newborns diagnosed with moderate to severe hypoxic ischemic encephalopathy HIE, a brain injury caused by lack of oxygen around birth. The study aims to reduce death or serious neurodevelopmental problems by 18 to 22 months of age. HIE is usually treated with cooling therapy, but this study explores caffeine as a potentially beneficial and low-cost alternative. Newborns at least 36 weeks gestation and weighing 1800 grams or more, diagnosed within six hours after birth, are randomly assigned to receive either caffeine or placebo. The caffeine group receives one 20 mgkg dose followed by two 10 mgkg doses at 24-hour intervals by mouth or feeding tube. The placebo group receives identical doses without caffeine. Sub-studies include blood sampling for caffeine levels, brain imaging with MRI, and cord blood collection for molecular analysis. Participants undergo assessments during hospitalization and follow-up visits up to 18 to 22 months old. Researchers measure survival and neurodevelopmental outcomes using physical exams, developmental tests, neurological scales, growth measures, and kidney function tests. Safety is monitored closely, and serious adverse events are recorded. The total study duration extends until final outcome assessments at nearly two years of age.
Actively Recruiting
Researchers are working to adapt and pilot the WHO Package of Essential Non-communicable Diseases PEN Plus intervention in Zambia to address the growing burden of complex chronic diseases such as diabetes, hypertension, and cancer. The study focuses on improving management of these diseases at first-level hospitals using an implementation framework designed to tailor interventions locally and prepare for national scale-up. This effort responds to increasing cases and insufficient primary care capacity in Zambia. The study involves adapting the PEN-Plus model through stakeholder engagement, training of frontline health workers, and establishing PEN-Plus clinics at selected peri-urban and rural hospitals. These clinics will provide care led by mid-level providers supported by specialists. The intervention includes supportive treatment, provision of necessary drugs and equipment, and integration with existing health information systems. The project will also develop national policies and operational plans to enable wider implementation. Participants are patients with chronic non-communicable diseases receiving care at first-level hospitals. Researchers will monitor implementation outcomes such as patient enrollment, care quality, and cost, as well as training outcomes for healthcare providers. Data collection includes routine visits and patient records integrated with national systems. The primary outcome measures the increase in patients diagnosed and managed according to WHO PEN-Plus guidelines over six years, with ongoing monitoring and evaluation of the program impact.
1-10 of 28
1